3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - UPDATE ON THE ONGOING ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)

被引：0
|
作者：
Derigs, P. [1 ]
Kunz, A. [1 ]
Dreger, P. [1 ]
Schmitt, A. [1 ]
Schubert, M. -L. [1 ]
Brueggemann, M. [2 ]
Bernhard, H. [3 ]
Kobbe, G. [4 ]
Lindemann, A. [5 ]
Rummel, M. [6 ]
Wang, L. [1 ]
Michels, B. [1 ]
Waldhoff, P. [1 ]
Korell, F. [1 ]
Laier, S. [7 ]
Ho, A. D. [1 ]
Mueller-Tidow, C. [1 ]
Schmitt, M. [1 ]
机构：
[1] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany
[3] Klinikum Darmstadt, Dept Internal Med 5, Darmstadt, Germany
[4] Univ Hosp Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[5] Onkol Ettlingen, Praxis Onkol, Ettlingen, Germany
[6] Univ Hosp Giessen, Dept Internal Med 4, Giessen, Germany
[7] German Red Cross Drk Blood Donat Serv Baden Wurtt, Inst Clin Transfus Med & Cell Therapy IKTZ, Heidelberg, Germany
来源：
HUMAN GENE THERAPY | 2023年 / 34卷 / 21-22期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P003
引用
收藏
页码：A7 / A8
页数：2
相关论文
共 50 条
  • [31] DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT UPDATE
    Miao, Xiaojuan
    Shuai, Yanrong
    Han, Ying
    Liu, Yilan
    Zhang, Nan
    Yao, Hao
    Wang, Xiao
    He, Guangcui
    Chen, Dan
    Fan, Fangyi
    Chang, Alex H.
    Su, Yi
    Yi, Hai
    BONE MARROW TRANSPLANTATION, 2024, 59 : 219 - 219
  • [32] A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma
    Straathof, Karin
    Flutter, Barry
    Wallace, Rebecca
    Thomas, Simon
    Cheung, Gordon
    Collura, Angela
    Gileadi, Talia
    Barton, Jack
    Wright, Gary
    Inglott, Sarah
    Edwards, David
    Barton, Claire
    Dyer, Karen
    Westwood, Nigel
    Loka, Thalia
    Depani, Sarita
    Howe, Karen
    Barone, Giuseppe
    Pule, Martin
    Anderson, John
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL
    Porter, David L.
    Kalos, Michael
    Frey, Noelle V.
    Grupp, Stephan A.
    Loren, Alison W.
    Jemision, Christina
    Gilmore, Joan
    McConville, Holly
    Capobianchi, James
    Lledo, Lester
    Chew, Anne
    Shen, Angela
    Wood, Patricia A.
    Litchman, Manuel
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2013, 122 (21)
  • [34] Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL
    Porter, David L.
    Frey, Noelle V.
    Melenhorst, J. Joseph
    Hwang, Wei-Ting
    Lacey, Simon F.
    Shaw, Pamela
    Chew, Anne
    Grupp, Stephan A.
    Capobianchi, James
    Gilmore, Joan
    Kalos, Michael
    Litchman, Manuel
    Lledo, Lester
    Loren, Alison Wakoff
    Mahnke, Yolanda
    Marcucci, Katherine T.
    McConville, Holly
    Shen, Angela
    Wood, Patricia A.
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2014, 124 (21)
  • [35] MANAGING RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS ON A PHASE I TRIAL RECEIVING AUTOLOGOUS CAR (CHIMERIC ANTIGEN RECEPTOR) T-CELLS GENETICALLY MODIFIED TO TARGET B CELL SPECIFIC ANTIGEN CD19
    Quintanilla, Hilda S.
    Miale-Mayer, Donna
    Llerandi, Diane
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E102 - E103
  • [36] TRANSCEND CLL 004: Minimal Residual Disease Negative Responses After Lisocabtagene Maraleucel (JCAR017), a CD19-Directed CAR T-Cell Product, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 16 - 18
  • [37] Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL
    Zhu, Fenlu
    Shah, Nirav N.
    Schneider, Dina
    Xu, Huiqing
    Chaney, Katherine
    Luib, Lawrence
    Keever-Taylor, Carolyn
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    Johnson, Bryon D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [38] A phase 1 trial of TLR2-costimulated third-generation anti-CD19 CAR T-cells for relapsed/refractory B non-Hodgkin lymphomas
    Weinkove, Robert
    George, Philip
    Fyfe, Robbie
    Nouri, Yasmin
    Dasyam, Nathaniel
    Ostapowicz, Tess
    Mester, Brigitta
    Giunti, Giulia
    Perera, Travis
    Jina, Hayden
    D'Souza, Alwyn
    Perret, Rachel
    Li, Peng
    Hermans, Ian
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 8 - 9
  • [39] Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-CelT), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B
    Narula, Gaurav
    Keerthivasagam, Swaminathan
    Jain, Hasmukh
    Dhamne, Chetan
    Tembhare, Prashant
    Subramanian, Papagudi Ganesan
    Patkar, Nikhil
    Poojary, Minal
    Nisar, Albeena
    Pandit, Deepali
    Pandit, Khushali
    Karulkar, Atharva
    Jaiswal, Ankesh Kumar
    Khan, Aalia
    Shah, Shreshtha
    Firfiray, Afrin
    Pendhari, Juber
    Asija, Sweety
    Chowdury, Ambalika
    Banik, Ankit
    Moulik, Nirmalya Roy
    Srinivasan, Shyam
    Bhosle, Shilpushp
    Hiregoudar, Sumathi
    Ojha, Shashank
    Nayak, Lingaraj
    Thorat, Jayshree
    Bagal, Bhausaheb
    Sengar, Manju
    Jindal, Nishant
    Chichra, Akanksha
    Mirgh, Sumeet
    Gokarn, Anant
    Punatar, Sachin
    Rajadhyaksha, Sunil
    Khattry, Navin
    Banavali, Shripad
    Highfill, Steven
    Shah, Nirali N.
    Purwar, Rahul
    BLOOD, 2023, 142
  • [40] Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naive/memory T cells for relapsed or refractory non-Hodgkin lymphoma
    Puliafito, Benjamin R.
    Walthers, Christopher
    Ji, Brenda
    Ghafouri, Sanaz N.
    Naparstek, Jacob
    Trent, Jacqueline
    Chen, Jia M.
    Roshandell, Mobina
    Harris, Caitlin
    Khericha, Mobina
    Schweppe, Thomas
    Berent-Maoz, Beata
    Gosliner, Stanley B.
    Almaktari, Amr
    Ceja, Melanie Ayala
    Allen-Auerbach, Martin S.
    Said, Jonathan
    Nawaly, Karla
    Mead, Monica
    de Vos, Sven
    Young, Patricia A.
    Oliai, Caspian
    Schiller, Gary J.
    Timmerman, John M.
    Ribas, Antoni
    Chen, Yvonne Y.
    Larson, Sarah M.
    CANCER RESEARCH, 2023, 83 (08)
12345